Fiscal Year Earnings Estimate on Halozyme Therapeutics, Inc.(HALO)

Halozyme Therapeutics, Inc.(HALO): For the most recent quarter end, Halozyme Therapeutics, Inc. reported Annual Earnings of $-0.23. Based on the filings, last years Annual Earnings was, $-0.25. For the most recent quarter end, HALO reported a surprise Earnings per Share of 14.81% . The consensus estimate for current quarter is $-0.3 and for the current fiscal year, the estimate is $-0.89. For the Next fiscal year, the estimate is $-0.9 based on the consensus.

Halozyme Therapeutics, Inc. has received $-0.3 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 5 Financial Advisor in the Stock Trading Firms. Among 5 Analysts, Bottom line EPS Estimate for the current quarter is $-0.34 while the top line estimate is $-0.24 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -1100%. Halozyme Therapeutics, Inc. reported better than expected with a surprise EPS of 14.81% or $0.04 during its most recent quarterly earnings. The Actual EPS was $-0.23 compared to the Estimated EPS of $-0.27.

Halozyme Therapeutics Last issued its quarterly earnings results on Nov 7, 2016. The company reported $-0.23 EPS for the quarter, beating the analyst consensus estimate by $ 0.03. Analyst had a consensus of $-0.26. The company had revenue of $31.90 million for the quarter, compared to analysts expectations of $33.82 million. The companys revenue was up 53.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.19 EPS.

Company has reported several Insider transactions to the SEC, on Aug 26, 2015, Laurie Stelzer (CFO) purchased 10,000 shares at 17.24 per share price.On Jun 22, 2015, Kenneth J Kelley (director) sold 20,000 shares at 21.00 per share price.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) witnessed a decline in the market cap on Wednesday as its shares dropped 3.52% or 0.44 points. After the session commenced at $12.46, the stock reached the higher end at $12.46 while it hit a low of $12.07. With the volume soaring to 993,176 shares, the last trade was called at $12.07. The company has a 52-week high of $14.38. The company has a market cap of $1,563 million and there are 129,490,070 shares in outstanding. The 52-week low of the share price is $7.175.

Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The companys broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The companys initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozymes highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine.

Halozyme

Add Comment